Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Hypertonic Saline Solution Versus Mannitol for Brain Relaxation During Craniotomies: An Updated Meta-analysis
Neuro-oncology
P4 - Poster Session 4 (11:45 AM-12:45 PM)
5-003
The choice between mannitol and hypertonic saline as the preferred osmotic agent for achieving brain relaxation during craniotomies still lacks a definitive consensus in the existing body of research. This lack of agreement can be attributed to limited sample sizes and substantial heterogeneity among the trials included in previous studies.
This meta-analysis intends to provide an updated review of the published literature by comprising the largest published to date on the comparison of HTS with MAN for brain relaxation during craniotomies.
MEDLINE, Embase, and Cochrane databases were systematically searched until August 02, 2023. Data was examined using the Mantel-Haenszel method and 95% confidence intervals (CIs). Heterogeneity was assessed using I² statistics. Meta-regression analysis was conducted to evaluate a possible link between Brain Relaxation Score (BRS) and tumor volume. R, version 4.2.3, was used for statistical analysis.
A total of 16 RCTs and 1,031 patients were included, of whom 631 (61%) underwent surgery for supratentorial tumor resection. Compared with mannitol, hypertonic saline achieved better rates of BRS (80% vs. 71%; OR 1.68; 95% CI 1.22–2.33; p=0.001; I²=0%), which was also demonstrated in the subgroup analysis of supratentorial brain tumor patients (78% vs. 65%; OR 2.02; 95% CI 1.36–2.99; p=0.0005; I²=0%); a minor number of patients requiring a second dose of osmotic agent (14% vs. 28%; OR 0.43; 95% CI 0.27–0.69; p=0.0003; I²= 0%); a lower fluid intake (MD -475.9341 mL; 95% CI -818.8952– -132.9730; p=0.007; I²=88%); and lower urine output (MD -462.0941 mL; 95% CI -585.3020– -338.8862; p=<0.001; I²=96%). Hospital length of stay and focal neurological deficits did not reach a statistically significant difference.
Our study shows that HTS has better benefits than mannitol, not only for brain relaxation. Furthermore, the study reveals, utilizing subgroup analysis, that patients with supratentorial brain tumors are more likely to benefit from HTS administration.
Authors/Disclosures
Artur Menegaz de Almeida
PRESENTER
Mr. Menegaz de Almeida has nothing to disclose.
Patricia Viana No disclosure on file
Gabriel Marinheiro Dos Santos-Bezerra No disclosure on file
Jessica Hoffmann Relvas No disclosure on file
Lucca Moreira Lopes No disclosure on file
Gustavo L. Guilherme, Sr. Mr. Guilherme has nothing to disclose.
João A. Zanette Giusti Mr. Zanette Giusti has nothing to disclose.
Paloma Oliveira No disclosure on file
Mauro André Cabral No disclosure on file
Renato Carvalho Santos No disclosure on file
Khalid Medani, MD (UCLA) Dr. Medani has nothing to disclose.